FindTrial
Sign In

Development of tools for early diagnosis of operable cancer

DEvelopment of Tools for Early diagnosis of operable Cancer with muTation enrichment plasma DNA sequencing and blood tumor marker

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
CRIS
Registry ID
KCT0003539
Enrollment
840
Registered
2019-02-20
Start date
2019-01-02
Completion date
Unknown
Last updated
2019-03-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

None listed

Sponsors

Kangbuk Samsung Medical Center
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Histologically confirmed malignancy or strongly suspicious malignancy on PET-CT / CT scanning 2. Patients scheduled for curative intended surgery and/or radiotherapy 3. No previous chemotherapy or radiotherapy before curative intended surgery 4. 20 years and older 5. Ability to provide written informed consent for blood sampling 6. Ability to understand the right to withdraw written informed consent without disadvantages

Exclusion criteria

Exclusion criteria: 1. Previous history of chemotherapy and/or radiotherapy and/or curative intended surgery before study enrollment. 2. Previous history of malignancy within 3 years 3. History of organ transplantation requiring immunosuppressive treatment or peripheral blood stem cell transplantation

Design outcomes

Primary

MeasureTime frame
Test's average performance using prediction tool in cancer patients (60%);Test's specificity using prediction tool in healthy individuals (99%)—

Secondary

MeasureTime frame
Sensitivity of mutation enrichment plasma DNA sequencing by tumor type—

Countries

Korea, Republic of

Contacts

Public ContactYun-Gyoo Lee

Kangbuk Samsung Medical Center

yungyoolee@gmail.com+82-2-2001-8554

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Feb 4, 2026